SEC Comment Letter for Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989) (OTLK) — Sep 26, 2017
Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989)
Date: Sept. 26, 2017 · CIK: 0001649989 · Accession: 0000000000-17-034162
AI Filing Summary & Sentiment
Letter
September 25, 2017 Lawrence A. Kenyon Chief Financial Officer Oncobiologics, Inc. 7 Clarke Drive Cranbury, New Jersey 08512 Oncobiologics, Inc. Preliminary Proxy Statement on Schedule 14A Filed September 14, 2017 File No. 001-37759Re: Dear Mr. Kenyon: We have reviewed your filing and have the following comment. Please respond to the comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to the comment, we may have additional comments. Preliminary Proxy Statement on Schedule 14A General 1. We note that that you are requesting shareholder approval of the issuance of a material amount of senior securities. Please advise why you have not provided the information responsive to Item 13(a) of Schedule 14A. See Item 11(e) and instruction 1 to Item 13 of Schedule 14A. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Lawrence A. Kenyon Oncobiologics, Inc. September 25, 2017 Page 2
Please contact Chris Edwards at (202) 551-6761 or Suzanne Hayes at (202) 551-3675 with any questions. Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
September 25, 2017 Lawrence A. Kenyon Chief Financial Officer Oncobiologics, Inc. 7 Clarke Drive Cranbury, New Jersey 08512 Oncobiologics, Inc. Preliminary Proxy Statement on Schedule 14A Filed September 14, 2017 File No. 001-37759Re: Dear Mr. Kenyon: We have reviewed your filing and have the following comment. Please respond to the comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to the comment, we may have additional comments. Preliminary Proxy Statement on Schedule 14A General 1. We note that that you are requesting shareholder approval of the issuance of a material amount of senior securities. Please advise why you have not provided the information responsive to Item 13(a) of Schedule 14A. See Item 11(e) and instruction 1 to Item 13 of Schedule 14A. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Lawrence A. Kenyon Oncobiologics, Inc. September 25, 2017 Page 2 Please contact Chris Edwards at (202) 551-6761 or Suzanne Hayes at (202) 551-3675 with any questions. Division of Corporation Finance Office of Healthcare & Insurance